2026-526171-32-00招募中1 期
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (7)
Loading locations...
相似试验
尚未招募
1 期
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)Systemic Lupus ErythematosusNCT07688980AstraZeneca92
招募中
2 期
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.2025-520918-64-00National And Kapodistrian University Of Athens20
招募中
3 期
Determine effectiveness of Anifrolumab In Systemic sclerosis2023-505976-31-00Astrazeneca AB112
招募中
3 期
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)2023-504022-19-01AstraZeneca AB84
已完成
1 期
Anifrolumab 皮下和静脉给药在中国健康成年受试者中的药代动力学和安全性研究自身免疫性疾病的成人患者CTR20243368AstraZeneca AB/
阿斯利康投资（中国）有限公司/
Vetter Development Services USA, Inc./
Fisher Clinical Services Inc.